ArticleNeuro-oncology advances

Validation of Bromodomain and Extraterminal proteins as therapeutic targets in neurofibromatosis type 2.

Joanne Doherty et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.